The issue of how and when to monitor low-molecular-weight heparin (LMWH) therapy was raised from the beginning of the clinical use of these compounds, almost 20 years ago. Laboratory monitoring of LMWHwas suggested mainly because the new compounds were to replace unfractionated heparin (UFH), which definitely required monitoring. In the following, we will briefly review the reasons for monitori...

background necrosis of skin flaps is considered as an important complication in reconstructive surgery. we conducted an experimental study to investigate the efficacy of low-molecular weight heparin, clopidogrel and their combination to improve the flap survival. methods forty male, adult sprague-dawlay rats were divided randomly into 4 groups. standard rectangular, distally based dorsal random...

The seven reviews and the eleven articles in this special issue provide an updated survey of recent research and developments in the ever-growing field of heparin, along with low molecular weight heparins (LMWHs) and glycosaminoglycans (GAGs).

Background The National Patient Safety Agency issued a rapid response report in July 2010 aimed at reducing treatment dose errors with low molecular weight heparins (LMWHs) (1). This states: “incident reports indicate patients renal function is often not taken into consideration when prescribing treatment doses of LMWHs. Not considering renal function was the leading causes of error resulting i...